A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rafael Bejar, MD, PhD
Aptose Biosciences Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center
Duarte, California, United States
- University of Southern California
Los Angeles, California, United States
- University of Miami
Miami, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- Ochsner Healthcare
New Orleans, Louisiana, United States
- Atlantic Hematological Oncology Center
Morristown, New Jersey, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University Hospital of Cleveland
Cleveland, Ohio, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Oct 2020
- Primary completion
- 15 Apr 2024
- Completion
- 15 Apr 2024
- Last update posted
- 7 Mar 2025
- Registered enrollment
- 45
- Registry id
- NCT04477291
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.